| Literature DB >> 31584928 |
Xinger Jiang1, Shaogang Li1, Xiaoming Qiu1, Jiwei Cong1, Jian Zhou1, Wuzhuang Miu1.
Abstract
BACKGROUND Curcumin is a polyphenol compound extracted from the root of the herb Curcuma longa, which is used in traditional Chinese medicine (TCM). Worldwide, colorectal carcinoma (CRC) is an increasing cause of morbidity and mortality. This study aimed to investigate the effects of increasing concentrations of curcumin on cell viability, proliferation, and apoptosis of SW620 human colonic adenocarcinoma cells cultured in vitro, and the signaling pathways involved. MATERIAL AND METHODS SW620 human colonic adenocarcinoma cells were cultured in curcumin at concentrations of 0, 4, 8, 16, and 32 μmol/l for 48 hours. Specific small interfering RNA (siRNA) was transfected into SW620 cells to silence the expression of caudal type homeobox-2 (CDX2). Cell viability was measured using the MTT assay. Flow cytometry evaluated cell apoptosis. Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR) were used to assess the nuclear translocation of b-catenin and the activation of Wnt signaling. RESULTS Curcumin reduced cell viability and increased apoptosis of SW620 human colonic adenocarcinoma cells in a dose-dependent way, and increased the expression of CDX2 but decreased ß-catenin nuclear translocation and the expression of Wnt3a, c-Myc, survivin, and cyclin D1. CDX2 silencing significantly reduced the effects of curcumin on SW620 human colonic adenocarcinoma cells. The nuclear translocation of ß-catenin, and expression levels of Wnt3a, c-Myc, survivin, and cyclin D1 were significantly higher in CDX2-silenced SW620 cells. CONCLUSIONS Curcumin reduced cell viability and increased apoptosis in SW620 human colonic adenocarcinoma cells by restoring CDX2, which inhibited the Wnt/ß-catenin signaling pathway.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31584928 PMCID: PMC6792517 DOI: 10.12659/MSM.918364
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Primers used in reverse transcriptase-polymerase chain reaction (RT-PCR).
| Gene | Direction | Primer sequence |
|---|---|---|
| c-Myc | Forward | 5′-CGCGGATCCCTGGATTTTTTTCGGGTAGTG-3′ |
| Reverse | 5′-CCGCTCGAGCGCACAAGAGTTCCGTAGCT-3′ | |
| Survivin | Forward | 5′-TGGACAAACAAAGAGCCAAGAA-3′ |
| Reverse | 5′-TAGAGCAAAGCCACAAAACCAA-3′ | |
| Cyclin D1 | Forward | 5′-CCGCCTCACACGCTFCCTCTC-3′ |
| Reverse | 5′-TCCTCCTCGGCGGCCTTGGGG-3′ | |
| GAPDH | Forward | 5′-TGCACCACCAACTGCTTA-3′ |
| Reverse | 5′-GGCATGGACTGTGGTCATGAC-3′ |
Figure 1Cell viability of SW620 human colonic adenocarcinoma cells cultured with increasing concentrations of curcumin. (A) The line chart shows the cell viability of SW620 human colonic adenocarcinoma cells cultured with curcumin at concentrations of 0, 4, 8, 16, and 32 μmol/l for 48 hours. (B) The columns indicate the cell viability of SW620 cells transfected with negative control (NC), small interfering RNA (siRNA), CDX2-siRNA, and curcumin at 32 μmol/l. a The significant difference compared with SW620 cells treated with curcumin at 0 μmol/l (P<0.05). b The significant difference compared with SW620 cells treated with curcumin at 4 μmol/l. c The significant difference compared with SW620 cells treated with curcumin at 8 μmol/l (P<0.05). d The significant difference compared with SW620 cells treated with curcumin at 16 μmol/l (P<0.05). e The significant difference compared with SW620 cells transfected with NC siRNA (P<0.05). f The significant difference compared with CDX2 siRNA-transfected SW620 cells treated with curcumin at 0 μmol/l (P<0.05). g The significant difference compared with NC siRNA-transfected SW620 cells treated with curcumin at 32 μmol/l (P<0.05).
Figure 2Apoptosis of SW620 human colonic adenocarcinoma cells cultured with increasing concentrations of curcumin. (A) The upper part of the chart shows the results of flow cytometry analysis of apoptosis of SW620 human colonic adenocarcinoma cells cultured with curcumin at concentrations of 0, 4, 8, 16, and 32 μmol/l for 48 hours. The columns in the lower part of the chart indicate the percentage of apoptotic cells. (B) The upper part of the chart shows the results of flow cytometry analysis of apoptosis of SW620 human colonic adenocarcinoma cells transfected with negative control (NC) siRNA, CDX2-siRNA, and curcumin at 32 μmol/l. Columns indicate the percentage of apoptotic cells. a The significant difference compared with SW620 cells treated with curcumin at 0 μmol/l (P<0.05). b The significant difference compared with SW620 cells treated with curcumin at 4 μmol/l. c The significant difference compared with SW620 cells treated with curcumin at 8 μmol/l (P<0.05).d The significant difference compared with SW620 cells treated with curcumin at 16 μmol/l (P<0.05). e The significant difference compared with SW620 cells transfected with NC siRNA (P<0.05). f The significant difference compared with CDX2-siRNA transfected SW620 cells treated with curcumin at 0 μmol/l (P<0.05). g The significant difference compared with NC siRNA-transfected SW620 cells treated with curcumin at 32 μmol/l (P<0.05).
Figure 3Western blot for the expression of nuclear β-catenin in SW620 human colonic adenocarcinoma cells cultured with increasing concentrations of curcumin. (A) Western blot of β-catenin and the internal reference, histone H3, are shown. The columns in the lower part show the relative expression levels of nuclear β-catenin in SW620 human colonic adenocarcinoma cells cultured with curcumin at concentrations of 0, 4, 8, 16, and 32 μmol/l for 48 hours. (B) The upper part shows the Western blot of β-catenin and histone H3. Relative expression levels of nuclear β-catenin in SW620 human colonic adenocarcinoma cells transfected with negative control (NC) small interfering RNA (siRNA), CDX2-siRNA and curcumin at 32 μmol/l are shown in the columns in the lower panel. a The significant difference compared with SW620 cells treated with curcumin at 0 μmol/l (P<0.05). b The significant difference compared with SW620 cells treated with curcumin at 4 μmol/l. c The significant difference compared with SW620 cells treated with curcumin at 8 μmol/l (P<0.05). d The significant difference compared with SW620 cells treated with curcumin at 16 μmol/l (P<0.05). e The significant difference compared with SW620 cells transfected with NC siRNA (P<0.05). f The significant difference compared with CDX2 siRNA-transfected SW620 cells treated with curcumin at 0 μmol/l (P<0.05). d The significant difference compared with NC siRNA-transfected SW620 cells treated with curcumin at 32 μmol/l (P<0.05).
Figure 4Reverse transcriptase-polymerase chain reaction (RT-PCR) for the relative expression levels of mRNAs of the genes for c-Myc, survivin, and cyclin D1, and Western blot for CDX2, Wnt3a, c-Myc, survivin, and cyclin D1 in SW620 human colonic adenocarcinoma cells cultured with increasing concentrations of curcumin. (A) The columns indicate the relative expression levels of mRNAs of the genes for c-Myc, survivin, and cyclin D1 in SW620 human colonic adenocarcinoma cells cultured with curcumin at concentrations of 0, 4, 8, 16, and 32 μmol/l for 48 hours. (B) The columns indicate the relative expression levels of mRNAs of the genes for c-Myc, survivin, and cyclin D1 in SW620 human colonic adenocarcinoma cells transfected with negative control (NC) siRNA, CDX2-siRNA and curcumin at 32 μmol/l. (C) Western blot for CDX2, Wnt3a, c-Myc, survivin, cyclin D1, and GAPDH are shown. (D) The columns show the relative expressions levels of CDX2, Wnt3a, c-Myc, survivin and cyclin D1 in SW620 human colonic adenocarcinoma cells cultured with curcumin at concentrations of 0, 4, 8, 16, and 32 μmol/l for 48 hours. (E) Western blot for CDX2, Wnt3a, c-Myc, survivin, cyclin D1, and GAPDH are shown. (F) The columns indicate the relative expressions levels of CDX2, Wnt3a, c-Myc, survivin, and cyclin D1 in SW620 human colonic adenocarcinoma cells transfected with negative control (NC) siRNA, CDX2-siRNA and curcumin at 32 μmol/l. a The significant difference compared with SW620 cells treated with curcumin at 0 μmol/l (P<0.05). b The significant difference compared with SW620 cells treated with curcumin at 4 μmol/l (P<0.05). c The significant difference compared with SW620 cells treated with curcumin at 8 μmol/l (P<0.05). d The significant difference compared with SW620 cells treated with curcumin at 16 μmol/l (P<0.05). e The significant difference compared with SW620 cells transfected with NC siRNA (P<0.05). f The significant difference compared with CDX2-siRNA transfected SW620 cells treated with curcumin at 0 μmol/l (P<0.05). g The significant difference compared with NC siRNA-transfected SW620 cells treated with curcumin at 32 μmol/l (P<0.05).